If you have been reading about selank and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
== Diagnosis == Heart disease is often undiagnosed until a serious problem occurs, such as heart attack or cardiac arrest. Regular checkups can lead to an early diagnosis and preventative treatment. Screening tests and risk assessments should begin around age 20 if one does not have any risk factors. Screenings should begin in childhood if one has risk factors such as obesity, sedentary lifestyle, or a family history of heart conditions. Healthcare providers will run blood tests to check for cholesterol, triglycerides, lipoproteins, sugar, or proteins that are a sign of inflammation.
N-methylimidazole is slightly more basic than imidazole but is otherwise similar, if more lipophilic. Many salts of [M(imidazole-1-R)6]2+ are known (R = alkyl, vinyl, etc.). 2-Methylimidazoles are somewhat bulky ligands owing to the steric clash between the 2-methyl group and other ligands in octahedral complexes. A modified benzimidazole ligand is found in all versions of vitamin B12.
==== Skinless ==== "Skinless" hot dogs use a casing for cooking, but the casing may be a long tube of thin cellulose that is removed between cooking and packaging, a process invented in Chicago in 1925 by Erwin O. Freund, founder of Visking. The first skinless hot dog casings were produced by Freund's new company under the name "Nojax", short for "no jackets" and sold to local Chicago sausage makers. Skinless hot dogs vary in surface texture, but have a softer "bite" than with natural casing. Skinless hot dogs are more uniform in shape and size and cheaper to make than natural casing hot dogs.
Sources: en.wikipedia.org
The missing technique that made radar practical was the use of pulses to determine range by measuring the time between the transmission of the signal and reception of the reflected signal. This would allow a single station to measure angle and range simultaneously. In 1924, two researchers at the Naval Research Laboratory in the United States, Merle Tuve and Gregory Briet, decided to recreate Appleton's experiment using timed pulsed signals instead of the changing wavelengths. The application of this technique to a detection system was not lost on those working in the field, and such a system was prototyped by W. A. S. Butement and P. E. Pollard of the British Signals Experimental Establishment (SEE) in 1931. The War Office proved uninterested in the concept and the development remained little known outside SEE.
Germany's military, the Bundeswehr (Federal Defence), is organised into the Heer (Army and special forces KSK), Marine (Navy), Luftwaffe (Air Force) and Cyber- und Informationsraum (Cyber and Information Domain Service) branches. In absolute terms, German military spending in 2025 was the fourth-highest in the world. In response to the 2022 Russian invasion of Ukraine, Chancellor Olaf Scholz announced that German military expenditure would be increased past the NATO target of 2%, along with a one-time 2022 infusion of 100 billion euros, representing almost double the 53 billion euro military budget for 2021. In 2023, military spending according to NATO criteria amounted to $73.1 billion, or 1.64% of the country's GDP, well below the NATO target of 2%. In 2026, Germany reported an estimated spending of $147.002 billion to NATO, exceeding said target at 2.69% of GDP. As of May 2024, the Bundeswehr has a strength of 180,215 active soldiers and 80,761 civilians. Reservists are available to the armed forces and participate in defence exercises and deployments abroad. Until 2011, military service was compulsory for men at age 18, but this has been officially suspended and replaced with a voluntary service. Since 2001 women may serve in all functions of service without restriction. According to the Stockholm International Peace Research Institute, Germany was the fourth-largest exporter of major arms in the world between 2021 and 2025. In peacetime, the Bundeswehr is commanded by the Minister of Defence.
The surgeon designs the nasolabial flap and sets its central axis at a 45-degree angle from the (long) axis of the nasal dorsum. The shape of the skin flap is cut from the wound template fabricated by the surgeon. An incision is made to the flap (without an anaesthetic injection of epinephrine), which then is elevated and oriented, in an inferior-to-superior direction, between the subcutaneous fat and the muscle fascia. The cutting continues until the skin flap can be freely transposed upon the nasal defect. A Burrow's triangle is excised from the skin between the medial border of the flap and the nasal dorsum; the triangle can be cut either before or after the elevation of the nasolabial. The flap then is bent back (reflected), and can be thinned (cut) under loupe magnification; however, a nasolabial flap cannot be thinned as easily as an axial skin-flap. After the nasolabial flap has been emplaced, the flap donor-site wound is sutured closed. For a wound of the lateral nasal wall that is less than 15 mm wide, the flap donor-site can be closed primarily, with sutures. For a wound wider than 15 mm—especially a wound that comprehends the alar lobule and the lateral wall of the nose—primary closure is not indicated, because such a wound closure imposes excessive stresses upon the skin flap, thereby risking either blanching (whitening) or distortion, or both. Such risks are avoided by advancing (moving) the skin of the cheek towards the nasofacial junction, where it is sutured to the deep tissues.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.